Company Encyclopedia
View More
name
CVRx
CVRX.US
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
1.380 T
CVRX.USMarket value -Rank by Market Cap -/-

Financial Score

13/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking74/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-91.88%E
    • Profit Margin-92.95%E
    • Gross Margin86.81%A
  • Growth ScoreB
    • Revenue YoY18.44%B
    • Net Profit YoY11.04%C
    • Total Assets YoY-12.80%E
    • Net Assets YoY-26.28%E
  • Cash ScoreC
    • Cash Flow Margin-107.59%D
    • OCF YoY18.44%B
  • Operating ScoreC
    • Turnover0.47C
  • Debt ScoreD
    • Gearing Ratio56.83%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Promising Future for CVRx: Buy Rating Supported by BENEFIT-HF Trial and Market Expansion

    William Blair analyst Brandon Vazquez maintains a Buy rating on CVRx stock, citing the BENEFIT-HF trial's potential to expand the U.S. market for heart failure patients and generate significant revenue. The trial could triple the total addressable market and, if CMS reimburses the Barostim device, add up to $50 million in revenue. Despite early-stage risks, the stock's valuation supports a positive outlook. Canaccord Genuity also reiterated a Buy rating with an $11.00 price target.

    Tip Ranks·
    US
    CVRX
    +0.36%
    Tip Ranks·
    US
    CVRX
    +0.36%

    CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference

    MINNEAPOLIS, Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- CVRx, Inc. ( NASDAQ: CVRX ) ( "CVRx" ) , a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the ...

    GlobeNewswire·
    US
    CVRX
    +0.36%
    GlobeNewswire·
    US
    CVRX
    +0.36%

    Johnson & Johnson Makes a Major Move with CVRx Stock Sale!

    Johnson & Johnson sold 52,532 shares of CVRx stock for $536,309 on November 10, 2025. CVRx reported a 10% revenue increase to $14.7 million in Q3, with improved gross margins at 87%. However, the company faced a net loss of $12.9 million due to rising R&D and interest expenses. Analysts have raised price targets for CVRx, which also filed a $150 million mixed securities shelf. CVRx updated its revenue guidance to $55.6-$56.6 million for the year, while TipRanks’ AI Analyst rates the stock as Neutral, citing growth but significant profitability challenges.

    Tip Ranks·
    US
    CVRX
    +0.36%
    US
    JNJ
    +0.75%
    Tip Ranks·
    US
    CVRX
    +0.36%
    US
    JNJ
    +0.75%

    Johnson & Johnson Reports Disposal of CVRx Inc. Common Shares

    Johnson & Johnson has reported the disposal of common shares of CVRx Inc. in a recent SEC filing. The transaction was submitted by Johnson & Johnson Innovation - JJDC, Inc., along with other beneficial owners. The full filing is accessible through the provided link. This news brief was generated by Public Technologies (PUBT) and is for informational purposes only, not to be considered as financial, investment, or legal advice.

    Reuters·
    US
    CVRX
    +0.36%
    US
    JNJ
    +0.75%
    Reuters·
    US
    CVRX
    +0.36%
    US
    JNJ
    +0.75%

    Owner Johnson & Johnson Sells 52,532 ($536.3K) Of CVRx Inc [CVRX]

    Johnson & Johnson Beneficial Owner of CVRx Inc [CVRX] filed a Form 4 on November 10, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/6/25-11/7/25TransactionSaleShares52,532Price$10.21Value$536,310Ending Holdings: 4,050,898 - IndirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    CVRX
    +0.36%
    Reuters·
    US
    CVRX
    +0.36%
    © 2025 Longbridge｜Disclaimer